Abstract:Background: Despite the well-documented efficacy of antidepressant agents for the treatment of major depressive disorder (MDD), initial treatment nonresponse rates are high. Recent years have seen an increase in research into predictive biomarkers toward improving diagnosis and individualized treatment. Among those, epigenetic mechanisms such as DNA methylation constitute promising candidate markers in predicting antidepressant treatment response in MDD. The present study sought to address epigenome-wide DNA methylation as a predictor of antidepressant treatment response in the largest sample to date of patients with MDD. Methods: Epigenome-wide DNA methylation was analyzed using the Infinium MethylationEPIC BeadChip in peripheral blood of n = 230 Caucasian patients with MDD receiving 6-week antidepressant treatment in a naturalistic in-patient setting as well as in a subsample of n = 107 patients primarily receiving continuous treatment with serotonin reuptake inhibitors or serotonin and norepinephrine reuptake inhibitors. Treatment response was assessed by means of the Hamilton Depression Scale. Results: No genome-wide significant hits were observed. Suggestive (P < 1E-5) epigenome-wide evidence was discerned for altered DNA methylation at 6 CpG sites (LOC102724467, LOC100506023, RSPO2, SAG, IL16, PRKCI) to predict response to naturalistic antidepressant treatment. In patients treated with serotonin reuptake inhibitors or serotonin and norepinephrine reuptake inhibitors, differential DNA methylation at 11 CpGs, for example, mapping to the TIMP2, VDAC1, or SORL1 genes, was suggestively associated with treatment response. Conclusions: The present results provide preliminary evidence for altered DNA methylation patterns to be associated with antidepressant treatment response in MDD. Provided significant replication in independent and larger samples, the present findings might in the future aid in clinical decision-making toward more individualized and thus more efficacious treatments of MDD.

Depressive disorder and antidepressants from an epigenetic point of view

Epigenetics and depressive disorders: a review of current progress and future directions

Epigenetic alterations in depression and antidepressant treatment

Deciphering Depression: Epigenetic Mechanisms and Treatment Strategies

Epigenetic Aging in Major Depressive Disorder: Clocks, Mechanisms and Therapeutic Perspectives

DNA methylation and clinical response to antidepressant medication in major depressive disorder: A review and recommendations

The Relationship between DNA Methylation and Antidepressant Medications: A Systematic Review

Epigenome-Wide DNA Methylation in Unipolar Depression: Predictive Biomarker of Antidepressant Treatment Response?

Genetic, epigenetic and posttranscriptional mechanisms for treatment of major depression: the 5-HT1A receptor gene as a paradigm

DNA methylation in depression and depressive-like phenotype: biomarker or target of pharmacological intervention?

Epigenetic mechanisms of stress and depression.

Molecular studies of major depressive disorder: the epigenetic perspective

Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression

Epigenetic Mechanisms in the Neurodevelopmental Theory of Depression

Neuroplasticity and depression: Rewiring the brain's networks through pharmacological therapy (Review)

The neurobiology of depression—revisiting the serotonin hypothesis. II. Genetic, epigenetic and clinical studies

Molecular Biological Aspects of Depressive Disorders: A Modern View

Drug Response-Related DNA Methylation Changes in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder

The genetics of selective serotonin reuptake inhibitors

Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants

Neurobiological Investigation of Depression: Unraveling the Biological Basis of a Complex Mental Health Challenge